MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX

Source: San Antonio Breast Cancer Symposium® Authors: Joyce O’Shaughnessy, Read More